Business
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)-- Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing
About this update from Contineum Therapeutics, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nContineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced participation in the following upcoming investor conferences:\n\n\n\nMorgan Stanley 22nd Annual Global Healthcare Conference, September 4-6, 2024, NY, NY:\n\n\nCarmine Stengone, Contineum’s President and CEO, will present on Wednesday, September 4, 2024, at 7:00 am ET.\n\n\n\n\n\n\n\nH.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024, NY, NY:\n\n\nCarmine Stengone will present on Tuesday, September 10, 2024, at 2:30 pm ET.\n\n\n\n\n\n\nThe presentations will be available via webcast on the Investors section of Contineum’s website and a replay will be available following conclusion of the presentations.\n\n\nAbout Contineum Therapeutics\n\n\nContineum Therapeutics (Nasdaq: CTNM) is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that Contineum believes, once modulated, may demonstrably impact the course of disease. Contineum has a pipeline of internally-developed programs to address multiple NI&I disorders. Contineum has two drug candidates in clinical trials, PIPE-791, an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS) and PIPE-307, a selective inhibitor of the M1 receptor, in clinical development for relapse remitting MS. PIPE-307 is being developed pursuant to a global license and development agreement between Contineum and Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, who has also announced plans to initiate a Phase 2 trial of PIPE-307 in depression in 2024.\n\n\nContineum is headquartered in San Diego, CA. For more information, please visit www.contineum-tx.com.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240828527257/en/\n\nCompany Contact:\nPeter Slover\nCFO\nir@...